Scorpius Holdings, Inc. (SCPX)
USD 0.12
(-8.93%)
USD 0.12
(-8.93%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -42.03 Million USD | 8.0% |
| 2022 | -45.68 Million USD | -28.99% |
| 2021 | -35.41 Million USD | -35.58% |
| 2020 | -26.12 Million USD | -34.69% |
| 2019 | -19.39 Million USD | -11.06% |
| 2018 | -17.46 Million USD | -33.13% |
| 2017 | -13.11 Million USD | 0.07% |
| 2016 | -13.12 Million USD | 37.55% |
| 2015 | -21.02 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -6.32 Million USD | 1.76% |
| 2024 Q2 | -8.69 Million USD | -37.59% |
| 2023 Q2 | -14.31 Million USD | -9.82% |
| 2023 Q3 | -11.05 Million USD | 22.74% |
| 2023 FY | -42.03 Million USD | 8.0% |
| 2023 Q1 | -13.03 Million USD | 16.44% |
| 2023 Q4 | -6.43 Million USD | 41.81% |
| 2022 Q2 | -9.91 Million USD | -32.26% |
| 2022 FY | -45.68 Million USD | -28.99% |
| 2022 Q4 | -15.6 Million USD | -23.71% |
| 2022 Q3 | -12.61 Million USD | -27.17% |
| 2022 Q1 | -7.49 Million USD | 36.58% |
| 2021 Q1 | -7.23 Million USD | 0.0% |
| 2021 FY | -35.41 Million USD | -35.58% |
| 2021 Q4 | -11.82 Million USD | -62.6% |
| 2021 Q3 | -7.27 Million USD | -9.98% |
| 2021 Q2 | -6.61 Million USD | 8.64% |
| 2020 FY | -26.12 Million USD | -34.69% |
| 2019 FY | -19.39 Million USD | -11.06% |
| 2018 FY | -17.46 Million USD | -33.13% |
| 2017 FY | -13.11 Million USD | 0.07% |
| 2016 FY | -13.12 Million USD | 37.55% |
| 2015 FY | -21.02 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.91 Million USD | -31.696% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -341.607% |
| Armata Pharmaceuticals, Inc. | -40.89 Million USD | -2.793% |
| Actinium Pharmaceuticals, Inc. | -51.92 Million USD | 19.044% |
| Azitra, Inc. | -7.61 Million USD | -451.864% |
| Can-Fite BioPharma Ltd. | -8.19 Million USD | -412.9% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -512.51% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | -44.979% |
| CEL-SCI Corporation | -31.47 Million USD | -33.537% |
| iBio, Inc. | -16.63 Million USD | -152.688% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | -69.944% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | -108.262% |
| Matinas BioPharma Holdings, Inc. | -23.76 Million USD | -76.858% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -199.142% |
| NovaBay Pharmaceuticals, Inc. | -5 Million USD | -740.139% |
| NanoViricides, Inc. | -8.51 Million USD | -393.561% |
| Oragenics, Inc. | -20.9 Million USD | -101.064% |
| BiomX Inc. | -27.68 Million USD | -51.823% |
| BiomX Inc. | -27.68 Million USD | -51.823% |
| Protalix BioTherapeutics, Inc. | 10.46 Million USD | 501.837% |
| Palatin Technologies, Inc. | -22.49 Million USD | -86.842% |
| Theriva Biologics, Inc. | -21.43 Million USD | -96.128% |